

SINOVAC: CHRONOLOGY OF KEY FACTS AND ISSUES

Date	Event
From the BEGINNING OF PRIVATIZATION to 2018 AGM	
<p>SAIF's proxy filing conveniently omits the effort led by the Management Consortium (including Advantech/Prime, Vivo Capital, SAIF and certain former Board members) to privatize SINOVAC at below-market prices (US\$7.00 per common share), sparking a battle for control with the Sinobioway Consortium.</p> <p>The Management Consortium would have succeeded in buying all SINOVAC shares at US\$7.00 per common share if 1Globe, SINOVAC's largest shareholder, had not stood up to its principles despite the fact that 1Globe was invited to join the Management Consortium.</p>	
Feb 1, 2016	SINOVAC announced the receipt of a non-binding privatization acquisition offer from the Management Consortium (led by Advantech, SAIF, Vivo and certain members of the Imposter Former Board) at US\$6.18 per common share.
Feb 4, 2016	Sinobioway Consortium (led by Sinobioway) made a privatization offer at an acquisition price of US\$7.00 per common share.
Mar 28, 2016	SINOVAC's Board purported to adopt the "Rights Agreement" (also referred to as the "poison pill").
Aug 16, 2016	The Incumbent Directors received a letter from Heng Ren Investments LP, a US-based shareholder of the Company, stating that it believed that the price of US\$6.18 per common share significantly undervalued the Company and requesting the Incumbent Directors, among other things, seek to increase the acquisition price by the Management Consortium.
Aug 17, 2016 – Dec 14, 2017	1Globe was invited to join the Management Consortium and the Sinobioway Consortium. Both consortia claimed to have the support of 1Globe, although 1Globe remained uncommitted to either consortium throughout.
Mar 3, 2017	1Globe sent a letter to the Board's special committee, in response to the invitation by the Management Consortium to join its consortium, in which 1Globe made it clear its principles for supporting and joining any privatization, which included, among others, requests for protecting all shareholders' interests and fair negotiations with all bidders including the Sinobioway Consortium.
Jun 26, 2017	SINOVAC announced decision to enter into a definitive agreement for privatization transaction with the Management Consortium at the acquisition price of US\$7.00 per common share.
Jun 28, 2017	Sinobioway Consortium made a revised offer at US\$8.00 per common share.
Jul 2, 2017	Following bids by the two consortia, the Incumbent Directors questioned whether the Sinobioway Consortium had sufficient funds in US dollars for the acquisition, in response to which the Sinobioway Consortium duly furnished the Incumbent Directors with a certificate of deposit from the CITIC Group, evidencing US\$2.5 billion of cash.
Aug 19, 2017	<p>1Globe organized a meeting with leaders of the Management Consortium (Weidong Yin, Chairman and CEO of the Company, a number of Incumbent Directors and investors) and the Sinobioway Consortium (Aihua Pan, Chairman of Sinobioway, and some key investors) to promote a collaborative approach to the privatization process between the two consortia and requested protection of shareholders' interests in the privatization process. A tentative agreement was reached as to collaboration between the two consortia, but this subsequently fell through.</p> <p>1Globe informed SINOVAC management and the Board about the 10% of shares held by its related parties, in addition to the approximately 23% ownership reported in 1Globe's Form 13-D (Ref: SINOVAC 20F 2017).</p>

Nov 22, 2017	The Company issued its 2016 annual report referencing various judgments issued by Chinese courts (a) finding that a former Chinese Food and Drug Administration official had engaged in bribery and that one of the individuals who had bribed him was a member of the then Incumbent Board; and (b) referencing eight of the Company's former and current salespersons in the context of bribery charges.
Dec 11, 2017	The Former Board independent committee wrote to 1Globe on behalf of the Incumbent Directors to confirm if 1Globe had agreed with the Management Consortium to support the US\$7.00 per common share buyout proposal as claimed by the Company's management. 1Globe reiterated its support for a collaborative approach to the buyout.
Dec 26, 2017	Record date for the Annual General Meeting ("AGM").
Dec 28, 2017	SINOVAC issued notice of the AGM to its shareholders. One of the three items of business includes " <i>the re-election of the</i> [Incumbent Directors]" including Weidong Yin, Yuk Lam Lo, Simon Anderson, Kenneth Lee and Meng Mei.
Jan 5, 2018	The Company filed Schedule 13E-3 and exhibits with the SEC in relation to the acquisition of the Company by the Management Consortium at the acquisition price of US\$7.00 per common share (SINOVAC was trading above US\$8.00 per common share at the time). The filing included notice of a special meeting of shareholders, a proxy statement and a proxy card for approving the acquisition agreement.
Jan 8, 2018	An annual meeting planning teleconference was held among attorneys of Peking University (V-Ming) Investment Holdings and Sinobioway. The meeting minutes, extracted from a lost computer, mistakenly identified Attorney James Chang (DLA Piper) as "representing 1Globe" at this AGM planning meeting. However, 1Globe has never engaged DLA Piper or worked with James Chang.
Jan 31, 2018	Sinobioway published an open letter from Sinobioway Consortium to all shareholders of SINOVAC Biotech Ltd setting out its concerns about breach of fiduciary duties by SINOVAC's Incumbent Board and urging shareholders not to re-elect the Incumbent Directors of SINOVAC at the AGM. Specifically, the open letter urged shareholders to ask SINOVAC to correct voting cards to allow votes against the re-election of the board of directors or to attend the AGM in person to vote against the Incumbent Board.
Feb 1, 2018	1Globe was invited by the Company to attend the AGM since 1Globe's shares were needed to meet the quorum requirements for the AGM.
Feb 2, 2018	Deadline for receipt by SINOVAC of shareholders' online proxy votes.
Feb 3-5, 2018	SINOVAC received and responded to emails from shareholders asking whether shareholders can vote against the re-election of the Incumbent Directors at the AGM. SINOVAC replied, stating that shareholders can withhold their votes as well as vote for another candidate should they wish.
Feb 6, 2018	<p>SINOVAC's AGM took place at Peking University's biotech park in Beijing. This AGM was scheduled to be the final AGM before the Management Consortium acquired the Company for US\$7.00 per common share.</p> <p>At the AGM, James Chang, acting as the proxy of JPMorgan with shares beneficially owned by OrbiMed, proposed motions, including to (i) amend the ballot paper provided by the Company to include an "Against All" option to vote against the Incumbent Directors; (ii) remove all Incumbent Directors except Yuk Lam Lo; and (iii) nominate the New Directors. There was a tabulation of the votes cast (both those cast or purportedly cast in-person at the AGM and those cast on-line prior to the AGM) which showed that the New Directors had obtained the majority of votes cast. However, the scrutineer did not declare the election results, stating that she needed to confirm the validity of the votes with the Company's Antiguan counsel.</p>

From 2018 AGM to the PRIVY COUNCIL RULING in JANUARY 2025 WITH ORDER ISSUED ON FEBRUARY 5, 2025	
<p>SAIF's proxy says it is in favor of dividends, but the Reconstituted Imposter Former Board Slate it seeks to elect NEVER declared a dividend to SINOVAC common shareholders during the seven years it was empowered to do so.</p> <p>SAIF's proxy also conveniently omits the invalid transactions undertaken by the very directors SAIF seeks to reseal that allowed Advantech/Prime, Vivo Capital and their cronies to loot billions of dollars from SINOVAC.</p> <p>In order to settle the Board election dispute and defend against the poison pill deployed by the Imposter Former Board against the 45% of shares that voted against them at the 2018 AGM, 1Globe's Chairman personally financed seven years of litigation that led to the victory in the final and non-appealable ruling by the Privy Council, upholding shareholders' rights in electing their Board of Directors and invalidating the dilutive poison pill. It is the Privy Council's ruling that made possible the restoration of fairness through dividend payouts that the rightful, current SINOVAC Board declared and is working tirelessly to distribute.</p>	
Feb 7, 2018	The day after the Company's AGM, the Incumbent Directors ("Imposter Former Board") authorized the Company to issue restricted shares to the Imposter Former Directors, who purported to waive the Rights Agreement to allow the issue to take place without causing a Trigger Event.
Mar 5, 2018	SINOVAC (controlled by the Imposter Former Board) announced the re-election of the Imposter Former Directors.
Mar 5, 2018	SINOVAC commenced (a) proceedings against 1Globe, OrbiMed Advisors LLC and other shareholders who voted against the re-election of Imposter Former Board in Delaware, asserting there has been a Trigger Event under the Rights Agreement; and (b) proceedings against 1Globe in Massachusetts, alleging breaches of disclosure requirements under US securities law.
Mar 13, 2018	1Globe filed claim in the Antiguan High Court, seeking declarations and orders under section 122 IBCA that: <ol style="list-style-type: none"> 1. a new slate of directors was duly elected at the AGM; 2. the New Directors be installed as SINOVAC's Board of Directors; and 3. the Incumbent Directors are no longer SINOVAC's directors, and any actions taken on behalf of SINOVAC at their direction after the AGM are null and void.
Apr 10, 2018	1Globe filed an application for interim relief in the Antiguan proceedings, including seeking an order for a new election of directors.
Jun 26, 2018	SINOVAC filed a motion for partial summary judgment in the Delaware proceedings seeking a declaration that 1Globe, OrbiMed and other shareholders who voted against the Imposter Former Board at the AGM triggered the Rights Agreement before the AGM with the purpose of retroactively diluting the votes of those shares that voted against the Imposter Former Board.
Jul 2, 2018	<p>The Company entered into a transaction with Vivo Capital, LLC and Prime Success, L.P. (Management Consortium members), agreeing to sell them 11,800,000 of the Company's common shares at US\$7.35 each, for an aggregate consideration of US\$86,730,000 (the "2018 PIPE Transaction"). The Rights Agreement was purportedly waived by the Imposter Former Board to allow the transaction to take place without causing a Trigger Event.</p> <p>Mr. Shan Fu (member of the Reconstituted Imposter Former Board Slate) of Vivo Capital also purportedly joined the Imposter Former Board as a director. The PIPE Transaction increased the shares held by Imposter Former Directors and their affiliated Management Consortium members from 29.9% to 40.7% of the Company's total share capital.</p>
Jul 9, 2018	Antiguan High Court Judge Godfrey P. Smith ("Smith J") refused 1Globe's application for an interim injunction in the Antiguan proceedings.

Jul 20, 2018	SINOVAC served and filed its Defense affidavit in the Antiguan proceedings.
Jul 31, 2018	Delaware Court of Chancery denied SINOVAC's motion for expedited trial date and postponed its proceedings pending the outcome of the Antiguan proceedings.
Aug 3, 2018	1Globe served and filed its Reply affidavit in the Antiguan proceedings.
Aug 17, 2018	Massachusetts proceedings were effectively stayed pending the outcome of the Antiguan proceedings.
Dec 3-5, 2018	Trial before Smith J in the Antiguan High Court.
Dec 19, 2018	Smith J handed down judgment in the Antiguan proceedings dismissing 1Globe's claim in relation to the AGM and declaring that the Rights Agreement was validly adopted as a matter of Antiguan law.
Jan 29, 2019	1Globe filed Notice of Appeal in the Court of Appeal of the Eastern Caribbean Supreme Court (the "Court of Appeal") against Smith J's decision.
Feb 18, 2019	SINOVAC passed a board resolution declaring a Trigger Event under the Rights Agreement by 1Globe, OrbiMed Advisors LLC and all other shareholders (representing 45.5% of shares outstanding) who voted against the Imposter Former Board at the AGM on the alternative ballots, which would lead to a significant dilution of the share ownership of these shareholders.
Feb 22, 2019	<p>The Company issued Common and Series B Preferred Shares (which were placed in trust until final distribution) under the Rights Agreement to all shareholders except to those who voted against the Imposter Board at the AGM and issued a press release about its decision to declare a Trigger Event. This implementation of the Rights Agreement would lead to a dilution of the ownership of shareholders who voted against the Imposter Former Board (representing 45.5% of the Company's total share capital) with an increase of the shareholding of the Imposter Former Board and their affiliated former Management Consortium members from 40.7% to 55% of the Company's total share capital.</p> <p>The Imposter Former Board's actions, including the invalid poison pill, directly caused SINOVAC's prolonged NASDAQ trading halt that has trapped the SINOVAC shareholders' investment for over six years and counting.</p>
Feb 27, 2019	1Globe applied for a status quo order in the Delaware proceedings, seeking an order that SINOVAC shall not distribute or cause to be distributed any of the Exchange Shares under the Rights Agreement to SINOVAC's shareholders until the final disposition of the Delaware action or further order.
Mar 4, 2019	1Globe applied for an interim injunction before the Court of Appeal, restraining SINOVAC from taking any steps to enforce the terms of the Rights Agreement.
Mar 6, 2019	Delaware Court granted 1Globe's application for a status quo order.
Apr 4, 2019	The Court of Appeal granted 1Globe's injunction application pending hearing of the appeal.
Apr 8, 2019	Delaware proceedings stayed until the resolution of 1Globe's appeal before the Court of Appeal.
Sep 18, 2019	Hearing of 1Globe's appeal before the Court of Appeal.
Jan 2020	1Globe's Chairman, Dr. Chiang Li (current Chairman of the SINOVAC Board), had a productive meeting with SINOVAC's CEO (Weidong Yin) at the Company's headquarters concerning paths forward for the Company and the importance of focusing on product development, and offered 1Globe's support to develop a vaccine against the novel coronavirus (COVID-19). Subsequently, there were several collaborative follow-up meetings between the two teams.

Apr 14, 2020	SINOVAC was selected as a key supplier of the COVID vaccine by the Chinese government and announced the approval of human clinical trial for its vaccine candidate against COVID-19 following the successful completion of preclinical development.
Apr 17, 2020	SINOVAC announced commencement of Phase I human clinical trial for its vaccine candidate against COVID-19.
May 22, 2020	<p>SINOVAC's R&D subsidiary (known as Sinovac Life Sciences Co., Ltd. / "SLS"), a wholly owned subsidiary of SINOVAC, received US\$15 million in convertible debt (at an 8% interest rate) from Advantech and Vivo Capital in exchange for a 15% equity interest in SLS.</p> <p>On March 31, 2020, SINOVAC's cash balance was US\$165.3 million, in addition to a short-term investment of US\$21.2 million. On June 30, 2020, SINOVAC's cash balance was US\$141.3 million, in addition to a short-term investment of US\$35.4 million.</p>
Jun 24, 2020	SINOVAC's CoronaVac® was approved for emergency use in China by Chinese authorities.
Dec 7, 2020	SLS received US\$500 million in funding from Sino Biopharmaceutical in exchange for a 15% equity interest in SLS.
Jun 2, 2021	World Health Organization authorized CoronaVac® for emergency use.
Jun 30, 2021	As of the end of June 2021, SINOVAC had delivered over one billion doses of CoronaVac® globally.
Jul 12, 2021	SINOVAC entered into an agreement to supply CoronaVac® to COVAX.
Dec 9, 2021	The Court of Appeal handed down a judgment dismissing 1Globe's appeal on all nine grounds.
Feb 21, 2022	The Court of Appeal extended the interim injunction until the final determination of 1Globe's application for leave to appeal to the Privy Council.
Feb 24, 2022	The Court of Appeal granted 1Globe conditional leave to appeal on Grounds 2-5 only (in relation to the AGM).
Apr 19, 2022	1Globe applied to the UK Privy Council for permission to appeal on Ground 9 (Rights Agreement Ground).
Feb 15, 2023	Privy Council granted 1Globe's consolidated application, subject to SINOVAC's right to contend that permission should not have been granted in some respects.
Apr 30, 2024	<p>Under the Imposter Former Board, SINOVAC issued its 2023 20-F (Annual Report) and noted: <i>"we have never declared or paid any dividends, nor do we have any present plan to pay any cash dividends on Sinovac Antigua's shares in the foreseeable future. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business."</i></p> <p>This statement was made after some members of the Former Management Consortium received more than US\$2 billion in dividends from SINOVAC's operating subsidiary.</p>
Jul 2024	The final substantive hearing before the UK Privy Council took place.
Jan 16, 2025	The UK Privy Council ruled in a final, non-appealable ruling that the nominees proposed by a group of shareholders at the 2018 AGM was the rightfully elected Board of SINOVAC. The Privy Council also ruled that the Company's Rights Agreement is void.

POST-PRIVY COUNCIL RULING (UNDER CURRENT SINOVAC BOARD) – PRESENT	
<p>The current SINOVAC Board, installed by the Privy Council and in accordance with Antiguan law, took office on February 8, 2025. Since then, it has immediately focused on restoring fairness by catching up on dividends for all valid SINOVAC shareholders, achieving understanding and gaining support from NASDAQ staff and leadership, implementing the Privy Council Judgment and Order, and formulating long-term development strategies.</p> <p>Despite facing resistance and challenges, the current SINOVAC Board successfully declared a special cash dividend of US\$55.00 per common share within 60 days of taking office.</p> <p>The Privy Council’s ruling enabled the current SINOVAC Board to nullify the unfair and irresponsible “no-dividends” policy of the Imposter Former Board to valid SINOVAC common shareholders. The Imposter Former Board instead selectively distributed dividends only to certain members of the former Management Buyout Consortium and Imposter Former Board. Some members of SAIF’s Reconstituted Imposter Former Board Slate have been distorting facts, attempting to rewrite history and launching a hostile campaign to smear the current SINOVAC Board and delay payment of the special cash dividend to valid SINOVAC shareholders.</p>	
Feb 5, 2025	<p>Pursuant to a court order (the “Order”) from the Judicial Committee of the Privy Council, the final court of appeal for Antigua and Barbuda and certain other Commonwealth jurisdictions, which is made up of five UK Supreme Court justices, found that, among other things, the slate of nominees proposed by a group of shareholders at the Company’s 2018 AGM was rightfully elected to the Board at that meeting. The Privy Council also concluded in the Judgment that there was nothing unlawful in 1Globe’s conduct.</p> <p>Following the 2018 AGM, the Imposter Former Board of Directors ceded office and the Privy Council ordered that, “The New Directors were therefore validly appointed and the Incumbent Directors have been <u>imposters</u> ever since.”</p>
Feb 28, 2025	<p>SINOVAC announced that, pursuant to the judgment made on January 16, 2025 (the “Judgment”) and the Order, the Board was rightfully installed and reconstituted in accordance with Antiguan law and was actively governing the Company.</p> <p>In its Judgment, the Privy Council recognized that, notwithstanding the possibility that some of the Board members validly elected at the 2018 Annual Meeting may no longer be willing or able to serve in their director capacity seven years later, the new Board is the only lawful Board of the Company.</p> <p>Based on the Judgment and Order, the new Board was reconstituted, adding new members to replace those who resigned, in accordance with Antiguan law. The Board is now led by a group of directors who are recognized and respected industry leaders with diverse backgrounds in healthcare, science and finance.</p>
Mar 18, 2025	SAIF filed amendment No.15 to the Schedule 13D, reporting that it had requisitioned the Special Meeting of the Company’s shareholders to remove three sitting directors and elect eight new director candidates.
Mar 28, 2025	The Company filed a press release announcing that Sven H. Borho, CFA, was appointed to the Board to fill a vacancy as a result of a recent resignation. As a qualified audit committee financial expert under NASDAQ Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board.
Apr 1, 2025	The Company announced that the Board declared a special cash dividend of US\$55.00 per common share (the “Dividend”). The Board expects to fund the Dividend from available cash resources of the Company and its subsidiaries, including prior distributions from Sinovac Life Sciences Co., Ltd. and other operating subsidiaries of the Company to Sinovac Biotech (Hong Kong) Limited. The Dividend is intended to provide the Company’s shareholders with their appropriate share of these prior distributions from the Company’s subsidiaries. Going forward, the Board also intends for shareholders to receive pro-rata distributions in due course with any distributions made to stakeholders of operating subsidiaries. The Board will work with the Company’s management to update the holders of its common shares on the expected record and payment dates for the Dividend as soon as practicable.

	<p>Pursuant to the Order, which found that the Board elected at the 2018 AGM, has served as the legitimate board of directors of the Company since then and to fulfill their fiduciary duties to the Company, the current members of the Board are assessing certain corporate actions taken by the former board of directors of the Company after they ceded office. One such corporate action being assessed is the issuance of the 11,800,000 common shares purportedly issued pursuant to a certain securities purchase agreement with Vivo Capital, LLC and Prime Success, L.P. in July 2018 (the “2018 PIPE Shares”), which was approved by the Imposter Former Board of Directors, whom the Privy Council held had not been lawfully acting as the Company’s Board. Following the determination of the record and payment dates for the Dividend, an amount equal to the aggregate amount of cash that would be payable under the Dividend in respect of the 2018 PIPE Shares, has been set aside and retained by the Company pending final resolution of any issues with respect to the 2018 PIPE Shares based on the Board’s assessment in accordance with the Order and under the laws of Antigua and Barbuda.</p>
Apr 28, 2025	<p>SAIF filed amendment No. 16 to the Schedule 13D regarding Cede & Co.’s submission, at SAIF’s request, of a requisition to convene a special shareholders’ meeting for the purpose of (i) removing certain board members from the Board as well as any other person or persons elected or appointed to the Board following February 8, 2025 and (ii) electing a new slate of nominees. This was SAIF’s second request to call a special meeting, because their initial request, made on March 18, 2025, was legally invalid.</p>
Apr 29, 2025	<p>SINOVAC’s Board issued a letter to shareholders, addressing the hostile actions and false claims by Vivo Capital, including a chronology of Vivo’s actions.</p>
Apr 30, 2025	<p>SINOVAC announced the record and distribution dates of the Dividend.</p>
May 20, 2025	<p>The Company disseminated a notice of special meeting of shareholders to valid shareholders of record as of May 19, 2025, that the Special Meeting will be held on July 8, 2025, the last day that the Special Meeting could legally be scheduled pursuant to Antiguan law.</p> <p>The Board asked SAIF to delay the Special Meeting, in order to allow the Company to complete the payment of the Dividend. SAIF did not respond to the request.</p>
Jun 12, 2025	<p>SINOVAC’s Board issued a letter to shareholders outlining a clear pathway to restore fairness and deliver value to all shareholders.</p>
Jun 16, 2025	<p>SINOVAC’s Board filed a press release alerting shareholders that on June 12, 2025, Advantech and Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust Company, and Equiniti (the dividend paying agent retained by the Board), which may prevent the Board from paying the Dividend as scheduled on or about July 9, 2025.</p> <p>Vivo Capital also indicated that they would challenge the Dividend and asked the paying agent to withdraw from facilitating the distribution of the Dividend to valid shareholders. The Board, in the press release, indicated its shock and disappointment by the self-serving, unnecessary actions by Advantech and Vivo Capital against the Company’s shareholders, which is threatening the rightful dividend payment to valid shareholders.</p>
Jun 16, 2025	<p>The Company held a Board meeting (the “June Board Meeting”), where the Board authorized Audit Committee Chair Sven H. Borho to accelerate payment of the Dividend, the previously announced special dividend of US\$55.00 per common share, which it now expects to be paid on or about July 7, 2025, in advance of the Special Meeting, subject to compliance with and approval by NASDAQ and the outcome of the Advantech/Prime Success lawsuit recently filed in New York. The Board’s acceleration of this payment is to ensure that, regardless of the outcome of the Special Meeting, all valid shareholders will receive the Dividend as an initial corrective step in ensuring fair and equitable distributions of dividends to all SINOVAC shareholders.</p> <p>Since the April 1 Announcement, the Board has learned that the Company’s operating subsidiary, Sinovac Life Sciences Co., Ltd., continued issuing additional dividends to its minority shareholders in the second half of 2024 while the Company was still under the control of the Imposter Former Board, with SINOVAC’s valid shareholders receiving nothing.</p>

	<p>Thus, the current Board has decided to declare a second special cash dividend (the “Second Dividend”) after the Special Meeting of US\$19.00 per common share. If the legal proceedings on PIPE shares conclude with cancellation of PIPE shares, the valid SINOVAC shareholders will receive an additional US\$3.73 per common share. The payout date for the Second Dividend is contingent upon fulfilling requirements set forth under the financial regulatory process.</p> <p>The Board also adopted a policy regarding the regular payment of dividends out of surplus cash above the amount needed to properly capitalize the Company and fund its operations. Based on a preliminary analysis, the Board believes this amount is between US\$20.00 – US\$50.00 per common share that could be distributed to SINOVAC shareholders in the future. This policy is another step the Board is taking to make common shareholders whole and restore fairness and equity for all valid shareholders who were previously excluded from distributions. The Board will work with the Company’s management to update the holders of its common shares on the expected record and payment dates for the dividend as soon as practicable.</p> <p>During the June Board Meeting, the Board also authorized the formal exploration of a future listing of SINOVAC shares on The Stock Exchange of Hong Kong and potentially other exchanges in order to stimulate liquidity, mitigate geopolitical risk, and maximize long term shareholder value.</p> <p>At the June Board Meeting, the Board also stated its commitment to holding an annual meeting of shareholders in the second quarter of 2026. Ahead of this Annual General Meeting, the Board will add new members and also introduce additional director nominees for election, ensuring the full slate has the combined skills, qualifications, and experience to best serve and oversee the Company’s strategy and operations, with the integrity and fiduciary commitment to fairly represent and make decisions in the best interests of the Company, while duly considering the interests of all SINOVAC shareholders. The slate is expected to include one or more representatives from SINOVAC’s management team, ensuring that the SINOVAC Board and management remain aligned on the Company’s long-term strategic goals, including accelerating the resumption of trading on NASDAQ and potentially other exchanges to maximize shareholders’ investment return.</p>
Jun 17, 2025	David Guowei Wang resigned from the Board, effective immediately. The Board appointed Geoffrey C. Hsu, CFA, to fill the vacancy under the laws of Antigua and Barbuda. David Guowei Wang’s resignation was due to other professional commitments and not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Hsu assumed David Guowei Wang’s committee appointments.
Jun 17, 2025	SINOVAC’s Board issued a press release announcing the update on special dividend payment and its commitment to delivering value to all SINOVAC shareholders.
Jun 18, 2025	SINOVAC’s Board filed its proxy statement with the SEC.